Aclaris Therapeutics (ACRS) Announces Statistically Significant Data from A-101 Phase 2 as Common Warts Treatment
Tweet Send to a Friend
Aclaris Therapeutics, Inc. (Nasdaq: ACRS) announced positive results from its Phase 2 clinical trial (WART-201), of A-101 Topical solution (A-101) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
